LISA - Life Science Austria’s Post

Reflecting on valuable information sharing between national trade associations This morning, I had the privilege of joining an insightful conversation and information sharing between industry experts from The Association of the British Pharmaceutical Industry (ABPI) and Danish Association of the Pharmaceutical Industry - Lif - Lægemiddelindustriforeningen The conversation focused on regulatory value and access policy environment for medicines in the UK and Denmark, sharing notes on current complexities, challenges and opportunities within the regulatory frameworks and the UK's appeal as a destination for life sciences investment. Key takeaways include the potential for regulatory improvements, the impact of international collaborations, and innovative pathways to market access for new medicines in both territories, underscoring the necessity of a patient-centric approach in developing regulatory systems for innovation in the pharmaceutical landscape Thanks to Daniel O'Connor, Orban Holdgate, Andy Collier, Louise Broe, Pernille Langgaard-Lauridsen, Thomas Klit Christensen and Joakim Steen Barron-Mikkelsen for a constructive and enlightening session. More of this please! #PharmaceuticalIndustry #RegulatoryAffairs #HealthTechnologyAssessment #InnovationInHealthcare #RegulatoryInnovation

Last week, MSD experts spoke at several #DIAEurope2024 panels. They lead insightful discussions on key healthcare topics, such as pharmaceutical innovation, emerging scientific trends, regulation proposals and review processes.    As our Associate Vice President, Global Regulatory Policy, Virginia Acha, describes: "We shared experiences and discussed practical steps to advance international regulatory alignment at #DIA2024 – it once again proves what a uniquely neutral forum it is to support progress."   We are already looking forward to the next edition!    Ivana Ferber, Sylvie Meillerais, Virginia Acha, Amira Younes, Mic McGoldrick, Leonardo Semprun, Inka Heikkinen,  DIA, EFPIA - European Federation of Pharmaceutical Industries and Associations

On July 15th, Pharma Innovation Forum Greece (PIF), initiated a public discussion about a “Framework Agreement” for a collaborative national pharmaceutical strategy in Greece. Labrina Barmpetaki, President of PIF and Ioannis Kotsiopoulos, PMP, MSc, PhD, General Manager of PIF, addressed the need to ensure timely and equitable access to innovative treatments, improve pharmaceutical policy sustainability and enhance Greece's competitiveness in South-East Europe. The agreement involves a trilateral decision-making structure including the Government, Pharmaceutical Industry Associations, and Patient Associations, with commitments to adequate funding, digital tools for demand control and increased investment in clinical research. PIF calls on the Greek Government and all stakeholders to collaborate in implementing this agreement as the foundation for a sustainable pharmaceutical policy for the benefit of patients and the national economy. #pifgreece #FrameWorkAgreeement

#CPHI Milano 2024: at the heart of the #pharmaceuticalindustry The world's leading trade fair for the pharmaceutical industry, will return to #Milan from 8 to 10 October 2024 at #FieraMilanoRho. With over 62,000 participants, more than 166 countries represented and 2,400 exhibitors, the 2024 edition of CPHI Milan promises to be the largest ever. An unmissable opportunity for your business: 🔹 Comprehensive overview of the entire pharmaceutical supply chain. 🔹 Italy: one of the leading producers and exporters of pharmaceutical ingredients in Europe. 🔹 A global event in a strategic region. Lombardy the beating heart of Italian pharmaceutical production: a hub for pharmaceutical research, development and production. 🔹 #FieraMilano: the ideal venue for a global event like CPHI. 🔹Ideal platform for launching new therapies and improving patient health globally. If you want to know more, we also talk about it in the latest article on our website - link in the first comment

🗓️ Yesterday i had the oppurtunity to attend 1st SFEE Summit organised by The Hellenic Association of Pharmaceutical Companies (SFEE) at the📍Megaron International Conference Center in Athens. 🇬🇷 🔍 Theme: “Redefining Value” and 📈 Focus Areas: • Greek Economy: Exploring the value of the pharmaceutical industry • Innovation: Discussing the role of pharmaceutical innovation • Healthcare Trends: Unveiling the latest trends in healthcare and pharma • Challenges & Opportunities: Addressing the Greek pharma sector’s challenges and opportunities 🚀 It was a great summit which facilitated in-depth discussions, explored solutions, and shared best practices to current challenges in pharmaceutical landscape while shaped the future of the pharmaceutical policy in Greece 🌿 🔗Last but not least, it was a great oppurtunity to connect with colleagues across healthcare industry during networking breaks #SfEE #SfEESummit #RedifingValue

14-15 March – Barcelona, Spain   Our final session at Clinigen Insights sees Claudia Martínez, Head of Research at the Access to Medicines Foundation, discuss the evolving landscape of access strategy integration within pharmaceutical companies' new product development. Gain invaluable insights into our industry's concerted efforts to enhance access in Low- and Middle-Income Countries (LMIC).   The session will be followed by a panel discussion and Q&A featuring experts from our Clinigen Regulatory, Commercial, and Consulting teams to delve into the nuances of the transition from Managed Access program to commercial strategy and explore novel approaches to non-launch market access for emerging treatments.   Find out more and RSVP (while places are still available): https://bit.ly/3GF1SJm   #managedaccess #expandedaccess #earlyaccess #realworlddata

IGES Group with HTA experts at BIO-Europe Spring 2024 The IGES Group is once again taking part in BIO-Europe Spring, one of the largest biopharma partnering events in Europe. BIO-Europe Spring 2024 will take place from 18 to 20 March in Barcelona. Up to 3,700 visitors from more than 2,000 companies from the field of innovative biotechnological medicinal products are expected to attend. IGES Group is taking part with experts from the life sciences sector. The aim is to enter into dialogue with researchers, companies and associations about international market access and reimbursement strategies for medical innovations. The focus of this year's discussions is the ongoing HTA harmonisation in Europe, one of the most far-reaching changes in EU pharmaceutical legislation. As EU-HTA stakeholders, companies of IGES Group have been involved in the public consultations on the development of guidelines and guidance documents as part of the EUnetHTA21 activities. IGES France Pharma Consulting will be on site for the first time as a new company of the IGES Group. Founded at the end of 2023, the company specialises in strategic and health economic consulting services for developers and manufacturers of pharmaceuticals who want to launch products on the market in France and Europe. The IGES Group as a whole offers a broad range of research and consulting services for global developers and manufacturers of pharmaceuticals, medical devices and digital health applications. The services support almost all phases of the product life cycle management of new developments. They are focussed on the most important European healthcare markets. #BIOEUROPE #Pharma #Medicines #HTA #IGES

💡 In keeping with our post-CRC activities, we'd like to bring you closer to our latest conference by sharing with you the insights provided by our panel of experts. Today, let's focus on Nathalie Stieger, Head of Government Affairs at Roche and Board Member of the Interpharma Association. Nathalie not only explained the favorable position of global pharmaceutical giant La Roche, but also, and above all, that of the entire Swiss pharmaceutical industry. Among the topics Nathalie addressed were: more accessible access to European labor and markets for Swiss companies, optimization of R&D conditions and, last but not least, Europe's global competitiveness in the face of American and Asian giants. 👉 Read the full article by following the link https://ow.ly/IMbQ50Qkyui

Melis Ersavcı Öztürk took her career from Spain to Türkiye, where she is now an intermediary between pharmaceutical companies and government agencies at the Association of Research-based Pharmaceutical Companies (AIFD | Araştırmacı İlaç Firmaları Derneği) What did she learn in the Bachelor of International Relations that helped her get to where she is today, and what does she have to say about IE University's faculty? Learn more in the carousel below, and check out more alumni stories from this Bachelor here: https://bit.ly/4a3FVAV

💊 Arterium took part in the Congress "Pharmacies of the World-2024" 🌍 🔸 This is an annual large-scale event in Ukraine that brings together players in the pharmacy retail and distribution sectors, pharmaceutical industry professionals, and regulatory bodies. 🔸 At the event, industry experts introduced participants to promising trends in the development of distribution and retail, discussed investments in the pharmaceutical sector, and presented analytical reviews and economic forecasts for the development of Ukraine's pharmaceutical market. This, in turn, will help build a business development strategy. 🔸 Such a strategy needs to be based on changes and initiatives from regulators, another key topic of the congress. This topic was addressed by Sergey Sur, Director of Arterium LTD. The Doctor of Pharmaceutical Sciences compared WHO's Good Regulatory Practices with the current regulatory practices in Ukraine. To reconcile the differences between them, stakeholders in Ukraine need to address several issues. In his presentation, Serhii Sur offered his own proposals for improving Ukraine's regulatory system. 🔸 We hope this will aid in the development of the pharmaceutical business in our country. Morion Proxima Research #Arterium #PharmaceuticalBusiness #developmentstrategy #regulatorysystem #Congress